View the Healthy People 2030 objectives for HIV and other sexually-transmitted infections here. This content originally appeared on hhs.gov. View the full article here. August 18th, 2020- Today, the U.S. Department of Health and Human Services released Healthy People 2030, the […]
This content originally appeared on hiv.gov. View the full article here. August 17th, 2020- To support the efforts of local partners to end the HIV epidemic in their communities, the U.S. Department of Health and Human Services (HHS) is announcing the […]
July 29th, 2020- Over 250 community providers, educators, and partners joined us for the webinar, “Gaining Patients’ Trust in the Age of COVID-19” on Wednesday, July 29th, 2020 from 11AM-12:30PM. With the ultimate aim of discussing the challenges of and […]
This article originally appeared on fda.gov. To see the full article, click here. July 2nd, 2020- Today, the U.S. Food and Drug Administration approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who have tried […]
This Special Issue of The American Journal on Drug and Alcohol Abuse (Impact Factor = 2.9) will include a mix of of original research reports, brief reports, systematic reviews , narrative reviews or qualitative research from drug and alcohol abuse […]
The following Op-Ed was written by Dr. Nina Harawa, CHIPTS Policy Impact Core Director. The full article published on indystar.com is available here. Nina T. Harawa July 8, 2020 6:00 AM As America labors under the effects of a global […]
July 9th, 2020- CHIPTS is excited to share preliminary reports from our three Ending the HIV Epidemic (EHE) supplement projects. These one-year, formative projects were funded by the National Institute of Mental Health to enhance the implementation science knowledge base […]
This article originally appeared on niaid.nih.org. To see the full article, click here. July 7th, 2020- A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than […]
This article originally appeared on hptn.org. To see the full article, click here. DURHAM, N.C. – Researchers from the HIV Prevention Trials Network (HPTN) announced today that the HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every 8 weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for HIV prevention among cisgender […]
Application Deadline: Tuesday, June 30, 2020 The Center for HIV Identification, Prevention and Treatment Services is pleased to announce scholarships for individuals who would like to attend the 23rd International AIDS virtual conference from July 6-10, 2020. The scholarship aims […]